Risk factors for HCV infection among young adults in rural New York who inject prescription opioid analgesics

American Journal of Public Health

Volumn 104, Issue 11, 2014, Pages 2226-2232

  Zibbell, Jon E ^a   Hart Malloy, Rachel ^b,c   Barry, John ^d   Fan, Lillian ^d   Flanigan, Colleen ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

^d Southern Tier AIDS Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NARCOTIC ANALGESIC AGENT;

ADOLESCENT; ADULT; AGE; COMPLICATION; EPIDEMIOLOGY; FEMALE; HEPATITIS C; HUMAN; MALE; PRESCRIPTION DRUG MISUSE; RISK FACTOR; RURAL POPULATION; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; ANALGESICS, OPIOID; FEMALE; HEPATITIS C; HUMANS; MALE; NEW YORK; PRESCRIPTION DRUG MISUSE; RISK FACTORS; RURAL POPULATION; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84907835478     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2014.302142     Document Type: Article

References (48)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med . 2006;144(10):705-714.
2. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156(4):271-278.
3. Amon JJ, Garfein RS, Ahdieh-Grant L, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis. 2008;46(12):1852-1858.
4. Schoener EP, Hopper JA, Pierre JD. Injection drug use in North America. Infect Dis Clin North Am. 2002;16(3):535-551, vii.
5. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol. 2008;168(10):1099-1109.
6. Klevens RM, Hu DJ, Jiles R, Holmberg SD. Evolving epidemiology of hepatitis C virus in the United States. Clin Infect Dis. 2012;55(suppl 1):S3-S9.
7. Hagan H, Pouget ER, Williams IT, et al. Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. J Infect Dis . 2010;201(3):378-385.
8. Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis. 2013;57(suppl 2):S32-S38.
9. National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention, Division of Viral Hepatitis. Surveillance for viral hepatitis-United States, 2011. Atlanta, GA: Centers for Disease Control and Prevention; 2011.
10. Centers for Disease Control and Prevention. Hepatitis C virus infection among adolescents and young adults - Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep . 2011;60(17):537-541.
11. Centers for Disease Control and Prevention. Rapid hepatitis C testing among persons at increased risk for infection - Wisconsin, 2012-2013. MMWR Morb Mortal Wkly Rep. 2014;63(14):309-311.
12. Banta-Green C. Heroin Trends Across Washington State. Seattle, WA: University of Washington Alcohol and Drug Abuse Institute; 2013.
13. Centers for Disease Control and Prevention. Use of enhanced surveillance for hepatitis C virus infection to detect a cluster among young injection-drug users - New York, November 2004-April 2007. MMWR Morb Mortal Wkly Rep. 2008;57(19):517-521.
14. Havens JR, Lofwall MR, Frost SDW, Oser CB, Leukefeld CG, Crosby RA. Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am J Public Health . 2013;103(1):e44-e52.
15. Havens JR, Oser CB, Leukefeld CG, et al. Differences in prevalence of prescription opiate misuse among rural and urban probationers. Am J Drug Alcohol Abuse. 2007;33(2):309-317.
16. Pollini RA, Banta-Green CJ, Cuevas-Mota J, MetznerM, Teshale E, Garfein RS. Problematic use of prescription-type opioids prior to heroin use among young heroin injectors. Subst Abuse Rehabil. 2011;2(1):173-180.
17. Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers - United States, 2002-2004 and 2008-2010. Drug Alcohol Depend. 2013; 132(1-2):95-100.
18. Young AM, Havens JR, Leukefeld CG. Route of administration for illicit prescription opioids: a comparison of rural and urban drug users. Harm Reduct J. 2010;7:24.
19. Lankenau SE, Schrager SM, Silva K, et al. Misuse of prescription and illicit drugs among high-risk young adults in Los Angeles and New York. J Public Health Res. 2012;1(1):22-30.
20. Centers for Disease Control and Prevention. Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse-Tennessee, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(1):1-4.
21. Centers for Disease Control and Prevention. Notes from the field: hepatitis C virus infections among young adults-rural Wisconsin, 2010. MMWR Morb Mortal Wkly Rep. 2012;61(19):358.
22. Maxwell JC. The prescription drug epidemic in the United States: a perfect storm. Drug Alcohol Rev. 2011;30(3):264-270.
23. Office of HIV/AIDS and Infectious Disease Policy. Hepatitis C Virus Infection in Young Persons Who Inject Drugs. Washington, DC: US Department of Health and Human Services; 2013.
24. Sadler GR, Lee HC, Lim RS, Fullerton J. Recruitment of hard-to-reach population subgroups via adaptations of the snowball sampling strategy. Nurs Health Sci. 2010;12(3):369-374.
25. US Department of Health and Human Services. Protection of Human Subjects, 45 CFR § 46. 2009.
26. Palmateer N, Hutchinson S, McAllister G, et al. Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data. J Viral Hepat. 2014;21(1):25-32.
27. Valdiserri R, Khalsa J, Dan C, et al. Confronting the emerging epidemic of HCV infection among young injection drug users. Am J Public Health. 2014;104(5):816-821.
28. Hosmer DW, Lemeshow S. Applied Logistic Regression. 3rd ed. Hoboken, NJ:Wiley-Interscience; 2002.
29. Kleinbaum DG, Kupper LL, Chambless LE. Logistic regression analysis of epidemiologic data: theory and practice. Commun Stat A-Theor. 1982;11(5):485-547.
30. Bruneau J, Roy E, Arruda N, Zang G, Jutras-Aswad D. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction . 2012;107(7):1318-1327.
31. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health. 2001;91(1):42-46.
32. Hagan H, Des Jarlais DC, Stern R, et al. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. Int J Drug Policy. 2007;18(5):341-351.
33. Lankenau SE, Teti M, Silva K, Jackson Bloom J, Harocopos A, Treese M. Initiation into prescription opioid misuse amongst young injection drug users. Int J Drug Policy. 2012;23(1):37-44.
34. Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction. 2010;105(5):844-859.
35. Surratt H, Kurtz SP, Cicero TJ. Alternate routes of administration and risk for HIV among prescription opioid abusers. J Addict Dis. 2011;30(4):334-341.
36. Katz N, Dart RC, Bailey E, Trudeau J, Osgood E, Paillard F. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011;37(4):205-217.
37. Battjes RJLC, Pickens RW. Age at first injection and HIV risk among intravenous drug users. Am J Drug Alcohol Abuse. 1992;18(3):263-273.
38. Hagan H, Thiede H, Des Jarlais DC, Hepatitis C. Virus infection among injection drug users. Epidemiology. 2004;15(5):543-549.
39. Roy E, Boudreau JF, Boivin JF. Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience. Drug Alcohol Depend. 2009;102(1-3):158-161.
40. Hagan H, Des Jarlais DC. HIV and HCV infection among injecting drug users. Mt Sinai J Med. 2000;67(5-6):423-428.
41. Roy E, Arruda N, Bourgois P. The growing popularity of prescription opioid injection in downtown Montreal: new challenges for harm reduction. Subst Use Misuse. 2011;46(9):1142-1150.
42. Zule WA, Bobashev G. High dead-space syringes and the risk of HIV and HCV infection among injecting drug users. Drug Alcohol Depend . 2009;100(3):204-213.
43. Doerrbecker J, Behrendt P, Mateu-Gelabert P, et al. Transmission of hepatitis C virus among people who inject drugs: viral stability and association with drug preparation equipment. J Infect Dis. 2013;207(2):281-287.
44. Doerrbecker J, Friesland M, Ciesek S, et al. Inactivation and survival of hepatitis C virus on inanimate surfaces. J Infect Dis. 2011;204(12):1830-1838.
45. Paintsil E, He H, Peters C, Lindenbach BD, Heimer R. Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. J Infect Dis. 2010;202(7):984-990.
46. Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006;41(6-7):777-813.
47. Pouget ER, Hagan H, Des Jarlais DC. Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. Addiction. 2012;107(6):1057-1065.
48. Brason FWRC, Dasgupta N. Project Lazarus: an innovative community response to prescription drug overdose. N C Med J. 2013;74(3):259-261.